Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 3/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23717502 | 0.93 | AR (0.35) | POLB | |
| SCHEMBL24363729 | 0.92 | POLB (0.38) | POLBHTR2CHTR2AHTR2BMEN1 | |
| SCHEMBL23683778 | 0.91 | POLB (0.38) | POLBHTR2CHTR2AHTR2BMEN1 | |
| SCHEMBL23685145 | 0.90 | CFTR (0.32) | POLBKMT2ACFTRGABRA5 | |
| SCHEMBL23717324 | 0.88 | CFTR (0.31) | CFTRGABRA5 | |
| SCHEMBL24345713 | 0.88 | CFTR (0.31) | HPGDCFTRALDH1A1GABRA5 | |
| SCHEMBL23717101 | 0.86 | CFTR (0.34) | HTR2ACFTRDRD4 | |
| SCHEMBL23683773 | 0.85 | AR (0.35) | POLBHTR2CHTR2BCFTR | |
| SCHEMBL24345695 | 0.85 | AR (0.35) | POLBHTR2CHTR2B | |
| SCHEMBL23685199 | 0.85 | AR (0.34) | P2RX7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | POLB 3294/4885HTR2C 2952/4885HTR2A 3621/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | POLB 3294/4885HTR2C 2952/4885HTR2A 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.